Prophylactic antiemetic effects in gynecologic patients receiving fentanyl IV-patient controlled analgesia: comparison of combined treatment with ondansetron and dexamethasone with metoclopramide and dexamethasone by Jee, Young Seok et al.
Korean J Anesthesiol 2010 November 59(5): 335-339 
DOI: 10.4097/kjae.2010.59.5.335  Clinical Research Article
Copyright ⓒ Korean Society of Anesthesiologists, 2010 www.ekja.org
Background: This study was conducted to compare the efficacy of a combination of ondansetron and 
dexamethasone with that of metoclopramide and dexamethasone for prevention of postoperative nausea and 
vomiting (PONV) in gynecologic patients receiving fentanyl IV-patient controlled analgesia.
Methods: One hundred patients were divided into two groups at random. In Group O, 5 mg of dexamethsone was 
administered after tracheal intubation, while 4 mg of ondansetron was administered at the end of surgery. In Group 
M, 5 mg of dexamethsone was administered after tracheal intubation and 20 mg metoclopromide was administered 
at the end of surgery. During the experiment, the PONV was evaluated at regular intervals. In addition, the incidence 
of nausea, and vomiting and the numerical rating scale (NRS) of nausea was measured (range, 0-10).
Results: The overall incidence of PONV in Group O was 22/50 (44%) while that in Group M was 19/50 (38%). There 
were no significant differences in the incidence of nausea, moderate to severe nausea (NRS of nausea, 4-10), or 
vomiting between groups. 
Conclusions: Treatment with a combination of 20 mg metoclopramide and 5 mg dexamethasone is an effective, 
safe, and inexpensive way to prevent PONV when compared to treatment with 4 mg ondansetron and 5 mg 
dexamethasone. (Korean J Anesthesiol 2010; 59: 335-339)
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Introduction
    Postoperative nausea and vomiting (PONV) is a continuing 
concern in surgical patients. PONV can cause patient 
discomfort and dissatisfaction, and may delay recovery room 
and hospital discharge. The risk of PONV during gynecological 
surgery with postoperative intravenous-patient controlled 
Analgesia (IV-PCA) is higher because being female and IV-PCA 
are risk factors of PONV [1].
    Ondansetron is a selective 5-hydroxytryptamine (5-HT3) 
receptor antagonist and dexamethason is a popular and effective 
combination therapy for prevention of PONV. However, ondan-
setron is an expensive drug; therefore, we should consider other 
optional combinations of drugs.
    When used in standard clinical doses (10 mg IV), metoclo-
pramide is ineffective for PONV prophylaxis [2]. Even in larger 
doses, metoclopramide does not appear to be an effective antie-
metic [3]. However, Wallenborn et al. [4] reported that 25 mg or 
50 mg metoclopramide combined with 8 mg dexamethasone 
administered intraoperatively is more effective at preventing 
PONV than 8 mg dexamethasone alone. Additionally, they 
reported that the addition of 25 mg or 50 mg metoclopramide 
to 8 mg dexamethasone (administered intraoperatively) is 
an effective, safe, and inexpensive method of preventing 
postoperative nausea and vomiting.
    This study was conducted to determine if treatment with a 
combination of 20 mg metoclopromide and 5 mg dexametha-
sone is as effective as treatment with 4 mg ondansetron and 5 
mg dexamethasone.
Materials and Methods
    This study was conducted with appropriate institutional 
approval, and written informed consent was obtained from 
all patients. We evaluated 100 female adult American Society 
of Anesthesiologists (ASA) physical status I and II patients 
undergoing gynecological operation with IV-PCA. Exclusion 
criteria were hypersensitivity to metoclopramide, ondansetron 
or dexamethasone, use of antiemetic drugs, presence of 
extrapyramidal motor disease, current steroid medication, liver 
or renal disease, and peptic ulcer. The patients enrolled in this 
randomized study were assigned to one of two prophylactic 
antiemetic regimens using computer generated random num-
bers. There were no significant differences in age, body weight, 
height, ASA, or PONV risk factors between groups (Table 1).
    Midazolam 3 mg was administered intramuscularly 30 minutes 
prior to the induction of anesthesia. Anesthesia was induced 
with 1% lidocaine (30 mg), propofol (1.5 mg/kg), and fentanyl 
(1 μg/kg), and tracheal intubation was facilitated by admini-
stering rocuronium (0.6 mg/kg). Additional rocuronium was 
administered as required. Anesthesia was maintained using 
2-3% sevoflurane (inspired concentration) and 50% nitrous 
oxide in oxygen. To reverse residual muscle relaxation, a 
combination of atropine (0.5 mg) and neostigmine (1 mg) were 
administered and the trachea was extubated. No opioids were 
given during the operation.
    A PCA infusor (Anaplus
Ⓡ AP1020, E-Wha Fresenius Kabi, Inc., 
Gunpo, Korea) 100 ml was prepared with 1,000 μg fentanyl and 
150 mg ketololac mixed with saline and then programmed to 
deliver a 0.5 ml bolus and a 2 ml/hr continuous infusion with a 
15-minute lockout interval.
    In both groups, 5 mg dexamethsone was administered 
after tracheal intubation. In Group O, 4 mg ondansetron 
was administered at the end of surgery. In Group M, 20 mg 
metoclopramide was administered at the end of surgery.
    The incidence of PONV and NRS of nausea were recorded by 
anesthesiology doctors at the following postoperative periods: 
0 to 1 hr, 1 to 6 hr, 6 to 12 hr, 12 to 24 hr, and 24 to 36 hr. The NRS 
of nausea was an 11-point scale, with 0 representing no nausea 
and 10 signifying the worst imaginable nausea. Delirium, 
extrapyramidal symptoms or arrhythmia were also recorded.
    Rescue antiemetic (ondansetron 1 mg) was given IV if 
a patient experienced more than 15 minutes of nausea, 
experienced a vomiting episode, or if the patient requested 
antiemetic medication. Treatment was repeated if necessary.
    Statistic calculations were performed using a standard 
statistical program (SPSS version 15.0, SPSS Inc., Chicago, 
IL, USA). The results were presented as the mean ± SD, and 
number of patients (%). Age, body weight, height, and duration 
of operation (minutes) were compared using a Student’s t-test. 
A chi-square test was used to analyze nominal data such as 
ASA, smoking habit, motion sickness or PONV history, type 
of surgery (laparoscopy/laparotomy) and overall incidence of 
Table 1. Patients’ Characteristics and PONV Risk Factors 
Group O
(n = 50)
Group M
(n = 50)
Age (yr)
Body weight (kg)
Height (cm)
ASA (I/II)
PONV risk factors 
    Smoking habit
    Motion sickness or PONV history
    Type of surgery 
     (laparoscopy/laparotomy)
Duration of operation (min)
37.1 ± 3.3
60.2 ± 8.9
159.7 ± 4.8
47/3
2
12
40/10
110.5 ± 20.9
38.7 ± 3.2
61.6 ± 6.8
159.5 ± 3.6
48/2
3
13
38/12
118.3 ± 18.3
Values shown are the mean number of patients ± SD or the number 
of patients (n). There were no significant differences between groups. 
PONV: postoperative nausea and vomiting, ASA: American Society 
of Anesthesiologists, Group O: ondansetron 4 mg + dexamethasone 
5 mg iv, Group M: metoclopramide 20 mg + dexamethasone 5 mg iv. 337 www.ekja.org
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PONV. To compare the time based incidence of nausea and 
vomiting between two groups, a longitudinal analysis based on 
logistic regression of the repeated measurements was adopted. 
Each of the observations of NRS of nausea for a given patient 
was treated as a binomial repeated measure, with a score of 0-3 
indicating no or mild nausea and 4-10 indicating moderate to 
severe nausea. A P < 0.05 was considered to indicate statistical 
significance.
Results
    The overall incidence of PONV in Group O was 22/50 (44%), 
while it was 19/50 (38%) in Group M. No differences were 
observed between groups. There were also no significant 
differences in the incidence of nausea (Table 2), the incidence 
of moderate to severe nausea (Table 3) or the incidence of 
vomiting (Table 4) between groups. Furthermore, side effects 
such as delirium, extrapyramidal symptoms or arrhythmia were 
not observed.
Discussion
    Without treatment, PONV occurs in 20-30% of the general 
surgical population and in up to 70-80% of high-risk surgical 
patients [5-7]. The adverse effects of PONV range from patient-
related distress to postoperative morbidity [8]. The most 
important patient-specific risk factors are female gender, 
nonsmoking status, and history of PONV/motion sickness 
[6,9-11]. High risk factors of PONV in Koreans are as follows in 
decreasing order: 1) being female, 2) history of PONV or motion 
sickness, 3) nonsmoker, 4) operative time of longer than 60 
minutes and 5) patient controlled analgesia [1]. According to the 
above Korean PONV risk model, most of the patients evaluated 
in this study had four out of the five risk factors (Table 1); 
therefore, the overall incidence of PONV in Group O was 44%, 
while it was 38% in Group M.
    Hill et al. [12] found that prophylaxis in high-risk patients was 
more cost-effective than placebo due to the increased costs 
associated with nausea and vomiting. Specifically, they found 
that the additional costs associated with PONV in placebo 
patients were up to 100 times greater than those associated 
with prophylaxis using a generic antiemetic and that the cost 
of treating vomiting was three times greater than the cost 
of treating nausea. Similarly, a study evaluating dolasetron, 
droperidol, or no prophylaxis in high-risk patients found that 
prophylaxis with either of the two antiemetics was more cost-
effective than no prophylaxis and subsequent rescue therapy 
[13]. The use of prophylactic antiemetics should be based 
on valid assessment of the patient’s risk for POV or PONV. 
In other words, antiemetic prophylaxis should be used only 
when the patient’s individual risk is sufficiently high. This can 
be estimated by multiplying the expected incidence (baseline 
risk) by the relative risk reduction resulting from prophylaxis. 
This approach produces a clinically meaningful decrease in 
the risk of PONV [5,14]. However, more liberal prophylaxis is 
appropriate for patients for whom vomiting poses a particular 
medical risk, such as those with wired jaws, increased 
intracranial pressure, gastric or esophageal surgery, or when the 
anesthesia care provider determines the need or the patient has 
a strong preference to avoid PONV [8]. 
    All 5-HT3 antagonists have been found to be equally antiemetic 
for the treatment of established PONV [15]. Combined treatment 
with metoclopramide and demenhydrinate is not effective 
when compared to treatment with metoclopramide alone [16]. 
Table 2. Incidence of Nausea
Group O
(n = 50)
Group M
(n = 50)
0-1 hr postoperatively
1-6 hr postoperatively
6-12 hr postoperatively
12-24 hr postoperatively
24-36 hr postoperatively
4 (8)
14 (28)
12 (24)
9 (18)
5 (10)
2 (4)
10 (20)
9 (18)
13 (26)
6 (12)
Values shown are the number of patients (%). There were no 
significant differences between groups. Group O: ondansetron 4 
mg + dexamethasone 5 mg iv, Group M: metoclopramide 20 mg + 
dexamethasone 5 mg iv.
Table 3. Incidence of Moderate to Severe Nausea 
Group O
(n = 50)
Group M
(n = 50)
0-1 hr postoperatively
1-6 hr postoperatively
6-12 hr postoperatively
12-24 hr postoperatively
24-36 hr postoperatively
0 (0)
6 (12)
3 (6)
1 (2)
1 (2)
0 (0)
2 (4)
2 (4)
2 (4)
0 (0)
Values shown are the number of patients (%). There were no 
significant differences between groups. Group O: ondansetron 4 
mg + dexamethasone 5 mg iv, Group M: metoclopramide 20 mg + 
dexamethasone 5 mg iv. 
Table 4. Incidence of Vomiting
Group O
(n = 50)
Group M
(n = 50)
0-1 hr postoperatively
1-6 hr postoperatively
6-12 hr postoperatively
12-24 hr postoperatively
24-36 hr postoperatively
0 (0)
5 (10)
6 (12)
4 (8)
1 (2)
1 (2)
4 (8)
2 (4) 
4 (8)
2 (4)
Values shown are the number of patients (%). There were no 
significant differences between groups. Group O: ondansetron 4 
mg + dexamethasone 5 mg iv, Group M: metoclopramide 20 mg + 
dexamethasone 5 mg iv. 338 www.ekja.org
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In addition, 10 mg metoclopramide plus metoclopramide 8 
mg metoclopramide is less effective than combined treatment 
with 8 mg dexamethasone and 4 mg ondansetron [17]. A meta-
analysis reported that 10 mg metoclopramide was clinically 
ineffective and did not improve when combined with 8 mg 
dexamethasone [2]. Moreover, 20 mg of metoclopramide was 
found to be ineffective when compared with dolasetron for 
prevention of PONV [18]. However, 20 mg of metoclopramide 
administered IV at the end of laparoscopic cholecystectomy 
resulted in a similar incidence of PONV as treatment with 8 
mg ondansetron [19]. When a low dose is administered at 
the beginning of surgery, metoclopramide will be ineffective 
because of the short-lasting effect of metoclopramide. The 
addition of 50 mg metoclopramide to 8 mg dexamethasone 
(given intraoperatively) is an effective, safe, and inexpensive 
method of preventing postoperative nausea and vomiting. 
A reduced dose of 25 mg metoclopramide administered 
intraoperatively with additional postoperative prophylaxis 
in high risk patients may be equally effective and cause 
fewer adverse drug reactions [4]. The recommended timing 
for administration of dexamethasone is at the induction of 
anesthesia rather than at the end of surgery [20]. Adverse events 
have not been noted after a single bolus dose of dexamethasone 
[21]. 
    Prophylactic doses of droperidol (0.625-1.25 mg IV) are 
effective for the prevention of PONV [22,23]. The droperidol 
doses used for the management of PONV are extremely low, 
and droperidol is unlikely to be associated with significant 
cardiovascular events at these dosing levels [24-26]. However, 
many physicians have stopped using droperidol due to the US 
Food & Drug Administration (FDA) black box restrictions on its 
use. As a result, droperidol for PONV is no longer available on 
the Korean market. 
    Combination therapy has superior efficacy than monotherapy 
for PONV prophylaxis [27,28]. Patients who are at high risk for 
PONV should receive prophylaxis with combination therapy. 
When different combinations were compared, no differences 
were observed between the 5-HT3 receptor antagonist plus 
droperidol; 5-HT3 receptor antagonist plus dexamethasone; and 
droperidol plus dexamethasone [7,29]. It has been suggested 
that, with combination therapy, dexamethasone doses should 
not exceed 10 mg IV and that droperidol doses should not 
exceed 1 mg IV. When used in combination with another drug, 
ondansetron doses in adults typically should not exceed 4 
mg, and can be much lower [30]. A large clinical trial of PONV 
revealed that 4 mg ondansetron, 4 mg dexamethasone, or 1.25 
mg droperidol were effective (odds ratios about 0.5), and that 
combinations of these drugs had an additive effect [7].
    In the present study, 20 mg metoclopramide was found to 
be as effective as 4 mg of ondansetron when combined with 
5 mg dexamethasone. Although adverse reactions such as 
extrapyramidal symptoms are rare, clinicians should be aware 
of them and be familiar with suitable treatment options.
    In conclusion, the results of our study demonstrate that treat-
ment with a combination of 20 mg metoclpromide and 5 mg 
dexamethasone is an effective, safe, and inexpensive way to 
prevent PONV when compared with combined treatment with 
4 mg ondansetrone and 5 mg dexamethasone in gynecologic 
patients receiving fentanyl IV-PCA.
References
1. Kim EJ, Ahn HJ, Park SH, Bang SR, Choi DH. Risk factors of 
postoperative nausea and vomiting: development of Korean risk 
model. Korean J Anesthesiol 2005; 48: 380-6.
2. Henzi I, Walder B, Tramèr MR. Metoclopramide in the prevention 
of postoperative nausea and vomiting: a quantitative systematic 
review of randomized, placebo-controlled studies. Br J Anaesth 
1999; 83: 761-71.
3. Apfel CC, Kranke P, Katz MH, Goepfert C, Papenfuss T, Rauch S, 
et al. Volatile anaesthetics may be the main cause of early but not 
delayed postoperative vomiting: a randomized controlled trial of 
factorial design. Br J Anaesth 2002; 88: 659-68.
4. Wallenborn J, Gelbrich G, Bulst D, Behrends K, Wallenborn H, 
Rohrbach A, et al. Prevention of postoperative nausea and vomiting 
by metoclopramide combined with dexamethasone: randomised 
double blind multicentre trial. BMJ 2006; 333: 324.
5. Tramèr MR. A rational approach to the control of postoperative 
nausea and vomiting: evidence from systematic reviews. Part I. 
Efficacy and harm of antiemetic interventions, and methodological 
issues. Acta Anaesthesiol Scand 2001; 45: 4-13.
6. Apfel CC, Läärä E, Koivuranta M, Greim CA, Roewer N. A 
simplified risk score for predicting postoperative nausea and 
vomiting: conclusions from cross-validations between two centers. 
Anesthesiology 1999; 91: 693-700.
7. Apfel CC, Korttila K, Abdalla M, Kerger H, Turan A, Vedder I, et al. A 
factorial trial of six interventions for the prevention of postoperative 
nausea and vomiting. N Engl J Med 2004; 350: 2441-51.
8. Gan TJ, Meyer TA, Apfel CC, Chung F, Davis PJ, Habib AS, et al. 
Society for Ambulatory Anesthesia guidelines for the management 
of postoperative nausea and vomiting. Anesth Analg 2007; 105: 
1615-28.
9. Cohen MM, Duncan PG, DeBoer DP, Tweed WA. The postoperative 
interview: assessing risk factors for nausea and vomiting. Anesth 
Analg 1994; 78: 7-16.
10. Stadler M, Bardiau F, Seidel L, Albert A, Boogaerts JG. Difference in 
risk factors for postoperative nausea and vomiting. Anesthesiology 
2003; 98: 46-52.
11. Choi DH, Ko JS, Ahn HJ, Kim JA. A Korean predictive model for 
postoperative nausea and vomiting. J Korean Med Sci 2005; 20: 811-5.
12. Hill RP, Lubarsky DA, Phillips-Bute B, Fortney JT, Creed MR, Glass 
PS, et al. Cost-effectiveness of prophylactic antiemetic therapy with 
ondansetron, droperidol, or placebo. Anesthesiology 2000; 92: 958-
67.
13. Frighetto L, Loewen PS, Dolman J, Marra CA. Cost-effectiveness 339 www.ekja.org
Korean J Anesthesiol Jee, et al.
of prophylactic dolasetron or droperidol vs rescue therapy in the 
prevention of PONV in ambulatory gynecologic surgery. Can J 
Anaesth 1999; 46: 536-43.
14. Tramèr MR, Walder B. Number needed to treat (or harm). World J 
Surg 2005; 29: 576-81.
15. Kazemi-Kjellberg F, Henzi I, Tramèr MR. Treatment of established 
postoperative nausea and vomiting: a quantitative systematic 
review. BMC Anesthesiol 2001; 1: 2.
16. Eberhart LH, Seeling W, Ulrich B, Morin AM, Georgieff M. 
Dimenhydrinate and metoclopramide alone or in combination for 
prophylaxis of PONV. Can J Anaesth 2000; 47: 780-5.
17. Maddali MM, Mathew J, Fahr J, Zarroug AW. Postoperative 
nausea and vomiting in diagnostic gynaecological laparoscopic 
procedures: comparison of the efficacy of the combination of 
dexamethasone and metoclopramide with that of dexamethasone 
and ondansetron. J Postgrad Med 2003; 49: 302-6.
18. Piper SN, Suttner SW, Rohm KD, Maleck WH, Larbig E, Boldt J. 
Dolasetron, but not metoclopramide prevents nausea and vomiting 
in patients undergoing laparoscopic cholecystectomy. Can J 
Anaesth 2002; 49: 1021-8.
19. Quaynor H, Raeder JC. Incidence and severity of postoperative 
nausea and vomiting are similar after metoclopramide 20 
mg and ondansetron 8 mg given by the end of laparoscopic 
cholecystectomies. Acta Anaesthesiol Scand 2002; 46: 109-13.
20. Wang JJ, Ho ST, Tzeng JI, Tang CS. The effect of timing of 
dexamethasone administration on its efficacy as a prophylactic 
antiemetic for postoperative nausea and vomiting. Anesth Analg 
2000; 91: 136-9.
21. Henzi I, Walder B, Tramèr MR. Dexamethasone for the prevention 
of postoperative nausea and vomiting: a quantitative systematic 
review. Anesth Analg 2000; 90: 186-94.
22. Domino KB, Anderson EA, Polissar NL, Posner KL. Comparative 
efficacy and safety of ondansetron, droperidol, and metoclopramide 
for preventing postoperative nausea and vomiting: a meta-analysis. 
Anesth Analg 1999; 88: 1370-9.
23. Fortney JT, Gan TJ, Graczyk S, Wetchler B, Melson T, Khalil S, et 
al. A comparison of the efficacy, safety, and patient satisfaction 
of ondansetron versus droperidol as antiemetics for elective 
outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. 
Anesth Analg 1998; 86: 731-8.
24. Gan TJ. Postoperative nausea and vomiting: can it be eliminated? 
JAMA 2002; 287: 1233-6.
25. White PF, Song D, Abrao J, Klein KW, Navarette B. Effect of low-dose 
droperidol on the QT interval during and after general anesthesia: a 
placebo-controlled study. Anesthesiology 2005; 102: 1101-5.
26. Charbit B, Albaladejo P, Funck-Brentano C, Legrand M, Samain E, 
Marty J. Prolongation of QTc interval after postoperative nausea and 
vomiting treatment by droperidol or ondansetron. Anesthesiology 
2005; 102: 1094-100.
27. Habib AS, Gan TJ. Combination therapy for postoperative nausea 
and vomiting: a more effective prophylaxis? Ambul Surg 2001; 9: 59-
71.
28. Eberhart LH, Morin AM, Bothner U, Georgieff M. Droperidol 
and 5-HT3-receptor antagonists, alone or in combination, for 
prophylaxis of postoperative nausea and vomiting: a meta-analysis 
of randomised controlled trials. Acta Anaesthesiol Scand 2000; 44: 
1252-7.
29. Habib AS, El-Moalem HE, Gan TJ. The efficacy of the 5-HT3 receptor 
antagonists combined with droperidol for PONV prophylaxis is 
similar to their combination with dexamethasone: a meta-analysis 
of randomized controlled trials. Can J Anaesth 2004; 51: 311-9.
30. Tramèr MR. A rational approach to the control of postoperative 
nausea and vomiting: evidence from systematic reviews. Part II. 
Recommendations for prevention and treatment, and research 
agenda. Acta Anaesthesiol Scand 2001; 45: 14-9.